[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Monte Rosa Therapeutics Inc (GLUE)

Monte Rosa Therapeutics Inc (GLUE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Monte Rosa Therapeutics Inc 321 HARRISON AVENUE SUITE 900 BOSTON MA 02118 USA

www.monterosatx.com Employees: 150 P: 617-949-2643

Sector:

Medical

Description:

Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON.

Key Statistics

Overview:

Market Capitalization, $K 1,583,517
Enterprise Value, $K 1,453,637
Shares Outstanding, K 80,016
Float, K 74,495
% Float 93.10%
Short Interest, K 13,399
Short Float 16.74%
Days to Cover 8.81
Short Volume Ratio 0.55
% of Insider Shareholders 6.90%
% of Institutional Shareholders 79.96%

Financials:

Annual Sales, $ 123,670 K
Annual Net Income, $ -38,630 K
Last Quarter Sales, $ 2,780 K
Last Quarter Net Income, $ -46,140 K
EBIT, $ -54,210 K
EBITDA, $ -45,850 K

Growth:

1-Year Return 279.12%
3-Year Return 335.90%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.55 on 03/17/26
Next Earnings Date 05/14/26 [--]
Earnings Per Share ttm -0.46
EPS Growth vs. Prev Qtr -66.67%
EPS Growth vs. Prev Year -339.13%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

GLUE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -15.12%
Return-on-Assets % -9.30%
Profit Margin % -31.24%
Debt/Equity 0.00
Price/Sales 13.05
Price/Cash Flow N/A
Price/Book 5.64
Book Value/Share 3.58
Interest Coverage -0.09
60-Month Beta 1.63
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.